Escondido, CA -- (ReleaseWire) -- 03/01/2021 --CB Scientific, Inc. (OTC:CBSC), through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring field. The CBSC FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Grand View Research, views the worldwide ECG industry as ripe for very high returns. The US Centers for Disease Control and Prevention (CDC) projects revenues to exceed $6.9 billion by 2021. CBSC is positioned to capture new market share from the current industry leaders in this field which include Biotelemetry (NASDAQ: BEAT) and IRHYTHM Technologies, Inc. (NASDAQ: IRTC).
Biotelemetry is currently trading at $40 with a market cap of $1.38B. CEO Charles Martin of CBSC was the Senior Director of Sales for Biotelemetry from 2014-2018. IRHYTHM is trading at $215 with a market cap of $6.19B and has gained of 300%+ in the last 52 weeks illustrating the powerful growth and interest in ECG recording devices today.
In 2019 there were 1,055,000 coronary events and in 2017 over 800,000 US deaths. There is a huge market for addressing this situation with an aging population subject to chronic diseases. Other factors favoring this market sector include the rise of digital health and telemedicine as well as growing pressure on healthcare to lower cost without sacrificing quality.
CBSC is growing internationally through strategic acquisitions and partnerships. CBSC has already acquired an innovative heart-monitoring intellectual property which is the basis of its' My-Cardia USA, and My-Cardia China. CBSC is expanding nationally into monitoring, testing facilities and services, and has agreements to accelerate this expansion. CBSC is also expanding its product portfolio and technology capabilities through internal activities and through agreements with third-party product developers and manufacturers.
CB Scientific, Inc. (OTC:CBSC) issues a Shareholder Update:
On February 18th CBSC provided an update on its progress and achievements since transitioning to the Ambulatory Remote Cardiac Monitoring market in June of 2020.
The CBSC targeted market deals directly with the early detection of heart rhythms that can contribute to heart disease. According to the World Health Organization (WHO), cardiovascular disease takes the lives of 17.9 million people every year, or 31% of all global deaths. They further state that by the year 2030, that number will grow to almost 23.6 million people who will die mainly from heart disease and stroke. In the US, the CDC states that 655,000 Americans die from heart disease each year - 1 in every four deaths. Heart disease costs the US alone approximately $219 billion each year. Early and timely detection of heart disease reduces hospital visits and leads to the avoidance of severe future problems. It reduces overall death rates because heart problems are identified and dealt with timely and proactively, reducing the high cost of care and improving the quality of life for the patient.
According to a recent press release from Market Research Engine, dated February 16, 2021, the cardiac monitoring and cardiac rhythm management market is expected to exceed more than US $26 Billion by 2024 at a CAGR of 4% in the given forecast. Their report covers various geographic regions such as North America, Europe, Asia Pacific, Latin American, Middle East, and Africa (https://www.marketresearchengine.com/cardiac-monitoring-and-cardiac-rhythm-management-market). The CBSC my-Cam device is part of this market.
Key accomplishments that CB Scientific, Inc. (OTC:CBSC) have achieved in the first seven months of operations include:
CBSC launched My-Cardia ECG product services in Thailand (1300+ hospitals - population 66.85 million) through authorized distributor, Mango Wellness, in October 2020, with expected new accounts in March 2021.
CBSC signed a Definitive Purchase Agreement to acquire US medical device manufacturer DATRIX LLC in October 2020, targeted to close in April 2021. Manufacturing of proprietary my-Cam cardiac event monitor from China to DATRIX has begun. Testing to incorporate the DATRIX Sirona acoustic and wireless device into My-Cardia cloud-based portal has started, which will provide additional alternative remote ECG devices to the CBSC product offering, both internationally and domestically.
CBSC received device registration and import authorization approval from the Medical Device Authority of Malaysia (384 hospital - population 32M) for the sale and distribution of our my-Cam device into that country, targeted launch in March 2021.
CBSC entered into a Collaborative Partnership Agreement with SHENZHEN SEMACARE MEDICAL TECHNOLOGY COMPANY, LTD. in February 2021. Our two companies will provide mutual assistance pursuing regulatory approvals for our individual products. CBSC will endeavor to consult and assist SEMACARE in their efforts towards regulatory approval of the MetaCor monitoring device for CE and US FDA 510(k) registration. SEMACARE will assist CBSC in the current regulatory approval process with the NMPA in China for the my-Cam monitoring device. During the term of this agreement, mutual efforts will be made towards the joint development of products, including interoperability between SEMACARE monitoring products and CB Scientific's current and future monitoring solutions. This includes assistance by SEMACARE to help develop a wireless, waterproof patch solution for CBSC devices.
CBSC is continuing ongoing clinical trials of the my-Cam device, associated cloud-based software portal, smartphone apps, and WeChat app continues in pursuit of NMPA (formally CFDA) device certification approval in China. Through January 2021, CBSC is in trials with its device in 40 hospitals, with more than 250,000 successful transmissions on the WeChat app. To date, CBSC maintains a 99%+ success rating. Along with assistance from SEMACARE, CBSC hopes to move closer to the approval of the device soon.
CBSC is completing its my-Cam device and software portal set-up to include regulatory and registration approval for the country of Singapore (population 5.8M), with a targeted distribution launch there in April 2021.
CBSC is also in final discussions to secure a Definitive Purchase Agreement to acquire an Independent Device Testing Facility (IDTF) in the US. With this acquisition, we would add the capabilities to immediately provide four necessary testing options, including 24-48hour Holter Monitoring, acoustic and wireless 30-day Cardiac Event monitoring, Mobile Cardiac Telemetry, and 3-21-day Extended Holter Monitoring. Remote patient monitoring is projected to grow 18% in the next five years, according to GlobalData, a leading data, and analytics company.
With the upcoming launch of distributors in the Asia Pacific region, the completion of the company's targeted acquisitions in the US, and the exploration of other geographic market expansions, CBSC is poised for significant growth in 2021 and beyond.
For more information on CB Scientific, Inc. (OTC:CBSC) visit: http://www.cbscientificinc.com
We are engaged in the business of marketing and advertising public companies for monetary compensation. Never invest in any stock featured on this page unless you can afford to lose your entire investment as trading stocks is very risky. INS Digital Media and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. INS Digital Media is compensated by third party shareholders to feature certain companies. These third parties may have shares and may liquidate the company's shares which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. INS Digital Media may, from time to time, purchase shares of public companies that we have been compensated to feature or profile in the open market and INS does this at fair market value. Release of Liability: Through use of this advertisement page viewing or using you agree to hold INS Digital Media and its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the Information. This is not a solicitation to buy stock.